Autoimmune Encephalitis Clinical Trials in Bron
3 recruitingBron, France
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Long-term Impact of NMDAR Encephalitis, Level 3
NMDAR Autoimmune Encephalitis
Hospices Civils de Lyon30 enrolled1 locationNCT07158229
Recruiting
Medium-term Effects of Treatments in Autoimmune Encephalitis
GFAPNMDAR Autoimmune EncephalitisLGI1 Antibody Associated Encephalitis+3 more
Hospices Civils de Lyon200 enrolled1 locationNCT07133113